Ceftazidime静注後の前立腺組織内および血清中濃度について
スポンサーリンク
概要
- 論文の詳細を見る
前立腺肥大症患者37例を三群に分け,それぞれCAZ 1 gを術前60分,120分および240分にone shot静注し,前立腺組織内および血清中濃度をTUR-Pの際に測定した.1)投与後60分にて採取した群:前立腺組織内濃度23.4±7.4 μg/g,血清中濃度45.0±15.9 μg/ml, P/S 0.58±0.27であった.2) 120分:それぞれ18.0±8.2 μg/g, 39.8±21.3 μg/ml, 0.53±0.31.3) 240分群:それぞれ11.3±3.2 μg/g, 22.3±9.6 μg/ml, 0.60±0.31であった.組織内濃度を起炎菌のMIC80と比較した場合,E. coliをはじめとする各種グラム陰性菌のMIC80を上回っていた.一方,各種標準菌に対しても,グラム陰性菌をはじめとしグラム陽性菌まで,広範囲の細菌のMICを上回っていた.したがってCAZは急性前立腺炎やTUR-Pの術前の感染予防に対し有用な薬剤であるThe present study was undertaken to evaluate the penetration of Ceftazidime (CAZ) into prostatic tissue (P) and serum (S). Thirty-seven patients with benign prostatic hypertrophy took part in this study. CAZ was administered intravenously at a dose of 1g preoperatively. Blood samples were taken simultaneously at the time of tissue sampling by transurethral resection of the prostate (TUR-P). The patients were divided into 3 groups. In group 1 (twelve patients), intravenous injection of the drug was given 60 minutes before tissue sampling. The mean concentrations of CAZ were 23.4 +/- 7.4 micrograms/g in the prostatic tissue and 45.0 +/- 15.9 micrograms/ml in the serum. In group 2 (thirteen patients), the injections were given 120 minutes before tissue sampling. The mean concentrations of CAZ were 18.0 +/- 8.2 micrograms/g in the prostatic tissue and 39.8 +/- 21.3 micrograms/ml in the serum. In group 3 (twelve patients), the injections were given 240 minutes before tissue sampling. The mean concentrations of CAZ were 11.3 +/- 3.2 micrograms/g in the prostatic tissue and 22.3 +/- 9.6 micrograms/ml in the serum. These findings indicate that CAZ is useful for the treatment of prostatitis and preventive medication before TUR-P.
論文 | ランダム
- 16チャネル液晶可変波長フィルタアレイを用いた波長多重光の信号選択実験
- 16チャネル液晶可変波長フィルタアレイを用いた波長多重光の信号選択実験
- 屋台5 : スターリングエンジンの教育への利用とその成果
- 分配選択型WDMシステム(SECURECAST)用16チャンネル波長可変液晶フィルタアレイの特性
- レンズ列導波路構造を持つアクティブアライメント型ボード間フリースペース光インタコネクション